GSK’s Ojjaara (Momelotinib) Receives the Health Canada’s Approval to Treat Myelofibrosis in Adults with Moderate to Severe Anemia
Shots:
- The HC has approved Ojjaara to treat splenomegaly and associated symptoms among anemic adults with intermediate or high-risk primary myelofibrosis, post polycythemia vera MF or post essential thrombocythemia MF
- Approval was based on the P-III (MOMENTUM) study data showing improvements in total symptom score (TSS), transfusion independence & splenic response rate, with additional support from P-III (SIMPLIFY-1) trial findings
- MOMENTUM trial compared Ojjaara (JAK 1 & 2 plus ACVR1 protein inhibitor) to danazol in symptomatic, anemic myelofibrosis patients previously treated with a JAK inhibitor while SIMPLIFY-1 study assessed Ojjaara vs ruxolitinib in myelofibrosis patients without prior JAK inhibitor treatment
Ref:GSK | Image: GSK
Related News:- GSK Receives the US FDA’s Approval of Ojjaara (momelotinib) for Myelofibrosis Patients with Anemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
